S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
Log in
NYSEAMERICAN:IBIO

iBio Stock Forecast, Price & News

$1.47
-0.07 (-4.55 %)
(As of 01/15/2021 08:00 PM ET)
Add
Compare
Today's Range
$1.46
Now: $1.47
$1.58
50-Day Range
$1.05
MA: $1.33
$2.05
52-Week Range
$0.23
Now: $1.47
$7.45
Volume171,429 shs
Average Volume19.59 million shs
Market Capitalization$267.70 million
P/E RatioN/A
Dividend YieldN/A
Beta-5.81
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. Its lead therapeutic candidate is IBIO-100 that is being advanced for investigational new drug development for the treatment of systemic scleroderma, idiopathic pulmonary fibrosis, and related conditions. The company is also developing vaccine candidates comprising IBIO-200 and IBIO-201, which are in preclinical development for the prevention of severe acute respiratory syndrome coronavirus 2; and IBIO-400 for the treatment of classical swine fever. In addition, it is developing recombinant proteins for third parties on a catalog and custom basis; and offers a range of process development, manufacturing, filling and finishing, and bio analytic services. iBio, Inc. has a license agreement with Planet Biotechnology, Inc. to develop therapeutics for infectious diseases; collaboration agreement with AzarGen Biotechnologies (Pty) Ltd (AzarGen) for the contract development and manufacturing services for AzarGen's development of a rituximab biosimilar/biobetter for the South African market; collaboration agreement with The Texas A&M University System for the development of coronavirus disease 2019 vaccine candidates; license agreement with the University of Natural Resources and Life Sciences, Vienna; collaboration with EdgePoint AI, a division of Mateon Therapeutics, Inc.; and collaboration agreement with CC-Pharming Ltd. iBio, Inc. is headquartered in New York, New York.

MarketRank

Overall MarketRank

1.34 out of 5 stars

Medical Sector

549th out of 1,556 stocks

Pharmaceutical Preparations Industry

278th out of 638 stocks

Analyst Opinion: 3.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Stock Exchange NYSEAMERICAN
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNYSEAMERICAN:IBIO
Previous SymbolNASDAQ:IBIO
CUSIPN/A
Phone+1-302-3550650
Employees43

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.64 million
Book Value$0.48 per share

Profitability

Net Income$-16,440,000.00
Net Margins-1,005.62%

Miscellaneous

Market Cap$267.70 million
Next Earnings Date2/12/2021 (Estimated)
OptionableNot Optionable
$1.47
-0.07 (-4.55 %)
(As of 01/15/2021 08:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive IBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for IBIO and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











iBio (NYSEAMERICAN:IBIO) Frequently Asked Questions

Is iBio a buy right now?

1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for iBio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" iBio stock.
View analyst ratings for iBio
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than iBio?

Wall Street analysts have given iBio a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but iBio wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is iBio's next earnings date?

iBio is scheduled to release its next quarterly earnings announcement on Friday, February 12th 2021.
View our earnings forecast for iBio
.

How were iBio's earnings last quarter?

iBio, Inc. (NYSEAMERICAN:IBIO) posted its quarterly earnings results on Monday, November, 16th. The biotechnology company reported ($0.05) EPS for the quarter, beating the Zacks' consensus estimate of ($0.08) by $0.03. The biotechnology company earned $0.41 million during the quarter. iBio had a negative return on equity of 55.71% and a negative net margin of 1,005.62%.
View iBio's earnings history
.

When did iBio's stock split? How did iBio's stock split work?

Shares of iBio reverse split before market open on Monday, June 11th 2018. The 1-10 reverse split was announced on Thursday, May 31st 2018. The number of shares owned by shareholders was adjusted after the closing bell on Friday, June 8th 2018. An investor that had 100 shares of iBio stock prior to the reverse split would have 10 shares after the split.

What price target have analysts set for IBIO?

1 brokerages have issued 1 year price objectives for iBio's shares. Their forecasts range from $2.00 to $2.00. On average, they anticipate iBio's stock price to reach $2.00 in the next twelve months. This suggests a possible upside of 36.1% from the stock's current price.
View analysts' price targets for iBio
or view Wall Street analyst' top-rated stocks.

Who are some of iBio's key competitors?

What other stocks do shareholders of iBio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other iBio investors own include Inovio Pharmaceuticals (INO), Vaxart (VXRT), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Heat Biologics (HTBX), Novavax (NVAX), Dynavax Technologies (DVAX), Co-Diagnostics (CODX), Nokia (NOK) and Moderna (MRNA).

Who are iBio's key executives?

iBio's management team includes the following people:
  • Mr. Thomas F. Isett III, CEO & Chairman (Age 55, Pay $1.03M)
  • Mr. Robert L. Erwin, Pres (Age 67, Pay $291.75k)
  • Mr. Robert B. Kay, Interim Sec., Interim Treasurer & Director (Age 80, Pay $324.69k)
  • Mr. John Delta, Principal Accounting Officer & Principal Financial Officer (Age 58)
  • Mr. Randy Joe Maddux, Chief Operating Officer (Age 59)
  • Dr. Renato Lobo, Chief Medical Officer
  • Dr. R. Barry Holtz, Pres of iBio CDMO
  • Carlos Picosse, Chief Exec. Officer of IBio Brazil

What is iBio's stock symbol?

iBio trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "IBIO."

How do I buy shares of iBio?

Shares of IBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is iBio's stock price today?

One share of IBIO stock can currently be purchased for approximately $1.47.

How big of a company is iBio?

iBio has a market capitalization of $267.70 million and generates $1.64 million in revenue each year. iBio employs 43 workers across the globe.

What is iBio's official website?

The official website for iBio is www.ibioinc.com.

How can I contact iBio?

iBio's mailing address is 600 Madison Ave Ste 1601, NEW YORK, NY 10022-1737, United States. The biotechnology company can be reached via phone at +1-302-3550650 or via email at [email protected]

This page was last updated on 1/18/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.